Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Insiders arent even buying at these prices

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Mar 12, 2022 12:42pm

225 Views

Post# 34509074

RE:RE:RE:Insiders arent even buying at these prices

You just keep focusing on people - the real investors will focus on value and competitive advantage.

You focus on who an alias might be - we'll focus on the science, the IP and the value of future IP.

You focus on your paper losses and stay angry - we'll focus on the funnel, the next opportunity and the real value of H2S as a gaseous mediator.

It's fun to watch !!!

-------------------

: )

<< Previous

Bullboard Posts

Next >>

Cross border trading in Canada and Australia